| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
a Department
of Rheumatology, LUMC, Leiden, The Netherlands, b Department of Immunohaematology and
Blood Bank, LUMC, Leiden, c Department of Hepato- gastroenterology, LUMC,
Leiden, d Department
of Pharmacology, Section Immunology, NV Organon, Oss, e QA/Statistical Department, NV Organon, Oss
Correspondence to: Dr K Vos, Department of Rheumatology, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands Email: kvos{at}rheumatology.azl.nl
Accepted for publication 24 January 2000
OBJECTIVE
To evaluate
plasma human cartilage glycoprotein (HC gp-39) as a possible marker for
the presence and/or activity of rheumatoid arthritis (RA) and other
inflammatory conditions.
BACKGROUNDHC gp-39 is
a secretory product of chondrocytes, synovial cells, macrophages, and
neutrophils. HC gp-39, also described as YKL-40, was found to be a
marker of joint disease and tissue injury in RA and various other diseases.
METHODSLevels of HC
gp-39 were determined by a sandwich enzyme linked immunosorbent assay
(ELISA) in 47 patients with RA, 47 with osteoarthritis (OA), 24 with
systemic lupus erythematosus (SLE), 24 with inflammatory bowel disease
(IBD), and in 47 healthy controls. A disease activity score was
assessed in the patients with RA, SLE, and IBD.
RESULTSThe plasma
level of HC gp-39 in the RA patient group was significantly higher than
in the other patient groups and healthy controls. The level in patients
with OA, SLE, and IBD was also significantly higher than the HC gp-39
level found in the healthy control group. HC gp-39 levels in patients
with RA correlated positively with the ESR and IgM rheumatoid factor
level but not with other variables of disease activity. In the patients
with SLE and IBD no correlation was found with the disease activity score.
CONCLUSIONThe plasma
level of HC gp-39 is increased in inflammatory conditions with and
without joint disease (SLE, IBD, OA, and RA). Thus increased levels of
HC gp-39 do not only reflect joint disease but also reflect
inflammation or tissue degradation in various conditions. Notably, the
highest level of HC gp-39 was found in patients with RA. Only in the RA
patient group was a correlation between HC gp-39 plasma levels and some
laboratory variables of disease activity found.
This article has been cited by other articles:
|
|
 |
|
  J. S. Johansen, B. V. Jensen, A. Roslind, D. Nielsen, and P. A. Price Serum YKL-40, A New Prognostic Biomarker in Cancer Patients? Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 194 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Punzi, M Podswiadek, R D'Inca, M Zaninotto, D Bernardi, M Plebani, and G C Sturniolo Serum human cartilage glycoprotein 39 as a marker of arthritis associated with inflammatory bowel disease Ann Rheum Dis, December 1, 2003; 62(12): 1224 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rehli, H.-H. Niller, C. Ammon, S. Langmann, L. Schwarzfischer, R. Andreesen, and S. W. Krause Transcriptional Regulation of CHI3L1, a Marker Gene for Late Stages of Macrophage Differentiation J. Biol. Chem., November 7, 2003; 278(45): 44058 - 44067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bernardi, M. Podswiadek, M. Zaninotto, L. Punzi, and M. Plebani YKL-40 as a Marker of Joint Involvement in Inflammatory Bowel Disease Clin. Chem., October 1, 2003; 49(10): 1685 - 1688. [Full Text] [PDF]
|
|
|
|
|
|
F. Fusetti, T. Pijning, K. H. Kalk, E. Bos, and B. W. Dijkstra Crystal Structure and Carbohydrate-binding Properties of the Human Cartilage Glycoprotein-39 J. Biol. Chem., September 26, 2003; 278(39): 37753 - 37760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Rakic, V. Lambert, M. Deprez, J.-M. Foidart, A. Noel, and C. Munaut Estrogens Reduce the Expression of YKL-40 in the Retina: Implications for Eye and Joint Diseases Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1740 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Riyazi, J Spee, T W J Huizinga, G M T Schreuder, R R P de Vries, F W Dekker, and M Kloppenburg HLA class II is associated with distal interphalangeal osteoarthritis Ann Rheum Dis, March 1, 2003; 62(3): 227 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Tsark, W. Wang, Y.-C. Teng, D. Arkfeld, G. R. Dodge, and S. Kovats Differential MHC Class II-Mediated Presentation of Rheumatoid Arthritis Autoantigens by Human Dendritic Cells and Macrophages J. Immunol., December 1, 2002; 169(11): 6625 - 6633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A A den Broeder, L A B Joosten, T Saxne, D Heinegard, H Fenner, A M M Miltenburg, W L H Frasa, L J van Tits, W A Buurman, P L C M van Riel, et al. Long term anti-tumour necrosis factor {alpha} monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation Ann Rheum Dis, April 1, 2002; 61(4): 311 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Vos, A. M. M. Miltenburg, K. E. van Meijgaarden, M. van den Heuvel, D. G. Elferink, P. J. M. van Galen, R. A. van Hogezand, E. van Vliet-Daskalopoulou, T. H. M. Ottenhoff, F. C. Breedveld, et al. Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions Rheumatology, December 1, 2000; 39(12): 1326 - 1331. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
